Fri, Jul 25, 2014, 5:36 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Ariad Pharmaceuticals Inc. Message Board

  • cristiichim19 cristiichim19 Apr 15, 2013 1:15 AM Flag

    Iclusig (Ponatinib) Used As First-Defense

    alang3's Instablog on seeking alpha

    When the FDA gave Ariad Pharmaceutical, Inc. early approval of its leukemia drug (Iclusig), it expected Iclusig to be used as a third (at most a second) defense. Yet, the FDA did not grant approval subject to any restriction on Iclusig being used as a first defense drug for the treatment of certain uncommon forms of leukemia.

    The valuation of the company has, so far, been based on its expected revenues based on sales of Iclusig as a third defense drug. Field research suggests, however, that the key assumptions in that valuation may be incorrect. Former short-sellers quickly abandoned their bearish positions on ARIA this week.

    Sentiment: Strong Buy

5.89-0.29(-4.74%)Jul 25 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.